Menu
No results found.
AFME
Affluent Medical SA – EPA
Weekly Share Price & Valuation Overview
Market Overview
Open
1.4400
Close
1.3800
High
1.4400
Low
1.3700
Trend
0.19692
Affluent Medical SA
France
• EPA - Euronext Paris
• AFME
• Currency: EUR
Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. The company offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. Affluent Medical SA was founded in 2011 and is headquartered in Aix-en-Provence, France.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- EUR 58.83M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- EUR 5.35M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- EUR 2.09M
- Revenue per Share (TTM) Estimated Total revenue divided by shares outstanding (may be estimated).
- EUR 0.14
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.41
- Shares Outstanding
- 39.22M
- Implied Shares Outstanding
- 40.36M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. EBITDA suppressed where implausible vs revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.24%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
39.03%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-2.75%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
6.40%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
16.37%
Sharemaestro House View
Confidence: 2
Sharemaestro internal conviction (0–3, higher is better).
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Composite Score: 2
Overall internal composite (0–3, higher is better).
Suggested Allocation: 3.33%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
—
Insiders
Shares held by company insiders (officers, directors).
21.9%
Institutions
Shares held by institutions (funds, pensions).
60.3%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
2.9%
Net Debt
Total debt − cash (negative = net cash).
None
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
100
Methodology Notes
- Revenue per Share (TTM) computed from resolved revenue ÷ shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
As of: 2025-08-18 03:54
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.